WO2021194287A1 - 신규한 산화 세륨 나노 복합체 및 이의 용도 - Google Patents
신규한 산화 세륨 나노 복합체 및 이의 용도 Download PDFInfo
- Publication number
- WO2021194287A1 WO2021194287A1 PCT/KR2021/003737 KR2021003737W WO2021194287A1 WO 2021194287 A1 WO2021194287 A1 WO 2021194287A1 KR 2021003737 W KR2021003737 W KR 2021003737W WO 2021194287 A1 WO2021194287 A1 WO 2021194287A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cerium
- poly
- acid
- nanocomposite
- cerium oxide
- Prior art date
Links
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 title claims abstract description 83
- 229910000420 cerium oxide Inorganic materials 0.000 title claims abstract description 81
- 239000002114 nanocomposite Substances 0.000 title claims abstract description 81
- 239000002105 nanoparticle Substances 0.000 claims abstract description 37
- 239000006185 dispersion Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000003381 stabilizer Substances 0.000 claims abstract description 27
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 10
- 206010061218 Inflammation Diseases 0.000 claims abstract description 8
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000010410 layer Substances 0.000 claims description 41
- 239000002245 particle Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- -1 poly(maleic acid) Polymers 0.000 claims description 27
- 229920002643 polyglutamic acid Polymers 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000027866 inflammatory disease Diseases 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 15
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 235000019441 ethanol Nutrition 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 13
- 206010040047 Sepsis Diseases 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 8
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 7
- 231100000283 hepatitis Toxicity 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000012792 core layer Substances 0.000 claims description 6
- IBMCQJYLPXUOKM-UHFFFAOYSA-N 1,2,2,6,6-pentamethyl-3h-pyridine Chemical compound CN1C(C)(C)CC=CC1(C)C IBMCQJYLPXUOKM-UHFFFAOYSA-N 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 4
- 102100035024 Carboxypeptidase B Human genes 0.000 claims description 4
- 239000012695 Ce precursor Substances 0.000 claims description 4
- 101000946524 Homo sapiens Carboxypeptidase B Proteins 0.000 claims description 4
- 101001102158 Homo sapiens Phosphatidylserine synthase 1 Proteins 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 4
- 102100039298 Phosphatidylserine synthase 1 Human genes 0.000 claims description 4
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- CETPSERCERDGAM-UHFFFAOYSA-N ceric oxide Chemical compound O=[Ce]=O CETPSERCERDGAM-UHFFFAOYSA-N 0.000 claims description 4
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 claims description 4
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- 239000011976 maleic acid Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 claims description 4
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 claims description 4
- 229920001444 polymaleic acid Polymers 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 3
- 208000006091 Primary angiitis of the central nervous system Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 3
- 208000017449 primary central nervous system vasculitis Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 2
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 206010003267 Arthritis reactive Diseases 0.000 claims description 2
- 229910004755 Cerium(III) bromide Inorganic materials 0.000 claims description 2
- 229910004664 Cerium(III) chloride Inorganic materials 0.000 claims description 2
- 229910008069 Cerium(III) iodide Inorganic materials 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000011200 Kawasaki disease Diseases 0.000 claims description 2
- 206010024652 Liver abscess Diseases 0.000 claims description 2
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010056956 Subacute hepatic failure Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 241000223996 Toxoplasma Species 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 201000004988 autoimmune vasculitis Diseases 0.000 claims description 2
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- WSVMKOQJZBJDJB-UHFFFAOYSA-H cerium(3+);oxalate;hydrate Chemical compound O.[Ce+3].[Ce+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O WSVMKOQJZBJDJB-UHFFFAOYSA-H 0.000 claims description 2
- AERUOEZHIAYQQL-UHFFFAOYSA-K cerium(3+);triacetate;hydrate Chemical group O.[Ce+3].CC([O-])=O.CC([O-])=O.CC([O-])=O AERUOEZHIAYQQL-UHFFFAOYSA-K 0.000 claims description 2
- KHSBAWXKALEJFR-UHFFFAOYSA-H cerium(3+);tricarbonate;hydrate Chemical compound O.[Ce+3].[Ce+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O KHSBAWXKALEJFR-UHFFFAOYSA-H 0.000 claims description 2
- QCCDYNYSHILRDG-UHFFFAOYSA-K cerium(3+);trifluoride Chemical compound [F-].[F-].[F-].[Ce+3] QCCDYNYSHILRDG-UHFFFAOYSA-K 0.000 claims description 2
- ZEDZJUDTPVFRNB-UHFFFAOYSA-K cerium(3+);triiodide Chemical compound I[Ce](I)I ZEDZJUDTPVFRNB-UHFFFAOYSA-K 0.000 claims description 2
- OZECDDHOAMNMQI-UHFFFAOYSA-H cerium(3+);trisulfate Chemical compound [Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O OZECDDHOAMNMQI-UHFFFAOYSA-H 0.000 claims description 2
- KKVSNHQGJGJMHA-UHFFFAOYSA-H cerium(3+);trisulfate;hydrate Chemical compound O.[Ce+3].[Ce+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KKVSNHQGJGJMHA-UHFFFAOYSA-H 0.000 claims description 2
- 229910000421 cerium(III) oxide Inorganic materials 0.000 claims description 2
- 229910000333 cerium(III) sulfate Inorganic materials 0.000 claims description 2
- 229910000422 cerium(IV) oxide Inorganic materials 0.000 claims description 2
- MOOUSOJAOQPDEH-UHFFFAOYSA-K cerium(iii) bromide Chemical compound [Br-].[Br-].[Br-].[Ce+3] MOOUSOJAOQPDEH-UHFFFAOYSA-K 0.000 claims description 2
- AHGQVCBMBCKNFG-KJVLTGTBSA-N cerium;(z)-4-hydroxypent-3-en-2-one;hydrate Chemical compound O.[Ce].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O AHGQVCBMBCKNFG-KJVLTGTBSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 206010019680 hepatic infarction Diseases 0.000 claims description 2
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000033300 perinatal asphyxia Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 210000000576 arachnoid Anatomy 0.000 claims 1
- XQTIWNLDFPPCIU-UHFFFAOYSA-N cerium(3+) Chemical group [Ce+3] XQTIWNLDFPPCIU-UHFFFAOYSA-N 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- SSBVJILJXCVPQD-UHFFFAOYSA-N heptahydrate;hydrochloride Chemical compound O.O.O.O.O.O.O.Cl SSBVJILJXCVPQD-UHFFFAOYSA-N 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 19
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 19
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 17
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 13
- 229960002684 aminocaproic acid Drugs 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 11
- 239000013641 positive control Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229940079877 pyrogallol Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 239000011258 core-shell material Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- 229910004631 Ce(NO3)3.6H2O Inorganic materials 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000004040 pyrrolidinones Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000010353 central nervous system vasculitis Diseases 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention relates to a cerium oxide nanocomposite modified with a biocompatible dispersion stabilizer and a composition for preventing or treating inflammatory diseases comprising the same as an active ingredient.
- Nanoparticles which are being used for various purposes in the field of diagnosis and treatment, exhibit new physical/chemical properties that are different from bulk materials in vivo due to their nanoscale microscopic size.
- nanoparticles exhibiting optimal physical properties suitable for their medical use by adjusting the composition, shape, size, and properties of the particles to suit the purpose is being actively developed.
- cerium oxide has thermal stability at high temperatures and has a redox action of Ce 4+ /Ce 3+ depending on the oxygen concentration around it due to its lattice structure, so that it is an electrolyte of a solid battery, a material of a UV filter, an oxygen sensor, and an optical device. It is being applied in various ways. In particular, in the medical field, due to its excellent ability to remove reactive oxygen species, it is in the spotlight as a therapeutic composition for a wide range of diseases caused by oxidative stress and inflammation.
- cerium oxide nanoparticles synthesized through a hydrothermal method which is one of the liquid phase methods, usually have a size of several hundred nm to several microns, making it difficult to precisely control the particle size and poor dispersibility. Accordingly, methods for producing cerium oxide nanoparticles having a smaller average particle diameter and a uniform particle size distribution have been proposed.
- the present inventors made intensive research efforts to develop an excellent cerium oxide nanostructure that maintains the intrinsic pharmacological effect while further improving the biomedical stability, biocompatibility and efficiency of the production process of nanoparticles.
- the biocompatible dispersion stabilizer layer is formed, it is possible to stably and economically mass-produce uniform and fine particles for a sufficient reaction time without applying a harsh environment such as a high temperature strong base and/or strong acid condition, thereby providing the present invention has been completed
- an object of the present invention is to provide a cerium oxide nanocomposite and a method for manufacturing the same.
- Another object of the present invention is to provide a composition for preventing or treating inflammatory or autoimmune diseases comprising the cerium oxide nanocomposite of the present invention as an active ingredient.
- a cerium oxide nanocomposite comprising:
- R 1 and R 2 are each independently hydrogen or oxygen, represents a single bond or a double bond, 1 is 1 or 2, and m is an integer from 100 to 1000;
- PGA polyglutamic acid
- PASP poly (aspartic acid)]
- alginate PAA [Poly (acrylic acid)], PMAA [Poly (methacrylic acid)], polymethyl methacrylic acid [poly (methyl methacrylic) acid)], PMA[poly(maleic acid)], PBMA[poly(butadiene/maleic acid)], PVPA[Poly(vinylphosphonic acid)], PSSA[Poly(styrenesulfonic acid)],
- An outer layer comprising at least one biocompatible dispersion stabilizer selected from the group consisting of polyvinyl alcohol (PVA) and dextran.
- the present inventors made intensive research efforts to develop an excellent cerium oxide nanostructure that maintains the intrinsic pharmacological effect while further improving the biomedical stability, biocompatibility and efficiency of the production process of nanoparticles.
- a polymer layer in which the monomer of the pyrrolidone derivative of Formula 1 is repeated on the cerium oxide nanoparticle core And it has been found that, when the biocompatible dispersion stabilizer layer is formed, uniform and fine particles can be stably and economically mass-produced for a sufficient reaction time without harsh environments such as high-temperature strong base and strong acid conditions.
- the nanocomposite of the present invention effectively overcomes the disadvantages of the prior art because it not only secures a time to secure a stable synthesis condition of a reaction time of about 2 hours under 70° C., but also does not require a strong acid or strong base environment.
- core layer refers to an innermost layer having only one surface in contact with other layers in a multi-layered composite.
- multilayer composite refers to a composite consisting of a plurality of layers composed of different components, and includes a laminated multilayer structure, a core-shell multilayer structure, and a combination thereof. forms are included without limitation.
- the multilayered composite of the present invention has a core-shell type multilayer structure in which nanoparticles are present in the center and the polymer of Formula 1 and a biocompatible dispersion stabilizer surround it on the outer shell.
- the term “inner layer” refers to a layer closer to the core than the outer layer
- the term “outer layer” refers to a layer that surrounds the inner layer of the core-shell structure and is located in the core rather than the inner layer. It means a distant floor.
- the inner layer does not necessarily have to be a layer in direct contact with the core layer, there may be additional layers closer to the core layer than the inner layer, and the outer layer also need not be the outermost layer and may additionally include an outermost layer located further from the core than the outer layer. .
- the boundary between the core layer and the inner layer is clearly distinguished, but the boundary between the inner layer and the outer layer may or may not be clearly distinguished.
- each component may be mixed in the subgroup or the entire section of the interface between the inner layer and the outer layer.
- polymer refers to a synthetic or natural high molecular compound in which the same or different types of monomers are continuously combined.
- polymers include homopolymers (polymers in which one type of monomer is polymerized) and interpolymers prepared by the polymerization of at least two different monomers, and interpolymers include copolymers (polymers prepared from two different monomers). polymers) and polymers prepared from more than two different monomers.
- the polymer of formula (1) used in the present invention is a homopolymer.
- alkyl refers to a straight-chain or branched saturated hydrocarbon group, and includes, for example, methyl, ethyl, propyl, isopropyl, and the like.
- C 1 -C 3 alkyl refers to an alkyl group having an alkyl unit having 1 to 3 carbon atoms, and when C 1 -C 3 alkyl is substituted, the carbon number of the substituent is not included.
- biocompatibility refers to a property that does not cause short-term or long-term side effects when administered in vivo and in contact with cells, tissues or body fluids of organs, specifically, causes tissue necrosis by contact with living tissues or blood.
- tissue compatibility and blood compatibility that does not coagulate or coagulate blood
- biodegradability that disappears after a certain period of time after administration in vivo and “excreted out of the body without accumulating after administration in vivo” It is meant to include “excretability”. Therefore, the term “biocompatible dispersion stabilizer” refers to a component that improves the dispersibility of particles while having the aforementioned biocompatibility.
- biodegradability refers to the property of being naturally decomposed when exposed to a physiological solution of pH 6-8, specifically, the lapse of time by body fluids, degrading enzymes, microorganisms, etc. in vivo. It means a property that can be decomposed according to
- the cerium oxide nanoparticles used in the present invention may be cerium(IV) oxide (CeO 2 ), cerium(III) oxide (Ce 2 O 3 ), or a mixture thereof.
- R 1 is hydrogen, R 2 is oxygen, and l is 1.
- R 1 is hydrogen, R 2 is oxygen, and l is 1.
- PVP polyvinylpyrrolidone
- the biocompatible dispersion stabilizer included in the outer layer is polyglutamic acid (PGA).
- PGA polyglutamic acid
- PGA may be poly- ⁇ -glutamic acid, poly- ⁇ -glutamic acid or poly- ⁇ -glutamic acid, specifically poly- ⁇ -glutamic acid.
- the poly- ⁇ -glutamic acid is poly L-glutamic acid (PLGA).
- the nanocomposite of the present invention further comprises a multifunctional ligand represented by the following formula 2:
- n is an integer of 3 to 7.
- multi-functional ligand refers to a molecule having two or more active functional groups and binding to two or more molecules, thereby serving as a linker between the molecules.
- the multifunctional ligand of Formula 2 used in the present invention has a carboxyl group capable of bonding to cerium oxide nanoparticles and an amine group capable of bonding with PVP of the inner layer and/or PGA, PVA or dextran of the outer layer. It allows the complex to be formed more efficiently and stably.
- n is 5.
- the compound of Formula 2 wherein n is 5 is 6-aminohexanoic acid (6-AHA).
- the nanocomposite of the present invention has an average particle diameter of 5 nm to 100 nm. More specifically, it has an average particle diameter of 5 nm to 80 nm and most specifically 5 nm to 50 nm.
- the present invention provides a composition for preventing or treating inflammation or autoimmune disease comprising the nanocomposite of the present invention as an active ingredient.
- cerium oxide nanocomposite used in the present invention Since the cerium oxide nanocomposite used in the present invention has already been described above, the description thereof is omitted to avoid excessive overlap.
- prevention refers to inhibiting the occurrence of a disease or disease in a subject who has never been diagnosed with a disease or disease, but is likely to have the disease or disease.
- the term “treatment” refers to (a) inhibiting the development of a disease, disorder or condition; (b) alleviation of the disease, condition or condition; or (c) eliminating the disease, condition or symptom.
- the composition of the present invention serves to suppress, eliminate, or alleviate the development of symptoms due to excessive or unwanted immune response or inflammation by reducing reactive oxygen species and suppressing the expression of inflammatory cytokines.
- the composition of the present invention may be a composition for treating these diseases by itself, or may be administered together with other pharmacological ingredients having an anti-inflammatory effect and applied as a therapeutic adjuvant for the above diseases.
- the term “treatment” or “therapeutic agent” includes the meaning of “therapeutic adjuvant” or “therapeutic adjuvant”.
- the term “administration” refers to directly administering a therapeutically effective amount of the composition of the present invention to a subject so that the same amount is formed in the body of the subject, and has the same meaning as “transplantation” or “injection”.
- the term “therapeutically effective amount” refers to the content of the composition contained in an amount sufficient to provide a therapeutic or prophylactic effect to an individual to whom the composition of the present invention is to be administered, and includes a “prophylactically effective amount”. it means
- the term “subject” includes, without limitation, humans, mice, rats, guinea pigs, dogs, cats, horses, cattle, pigs, monkeys, chimpanzees, baboons or rhesus monkeys. Specifically, the subject of the present invention is a human.
- the inflammatory or autoimmune disease to be prevented or treated with the composition of the present invention is rheumatoid arthritis, reactive arthritis, type 1 diabetes, systemic lupus erythematosus, multiple sclerosis, idiopathic pulmonary fibrosis, polymyositis, skin Myositis, localized sclerosis, systemic sclerosis, inflammatory bowel disease, Sjogren's syndrome, Raynaud's phenomenon, Bechet's disease, Kawasaki's disease, primary biliary sclerosis ), primary sclerosing cholangitis, ulcerative colitis, Crohn's disease, psoriasis, myasthenia gravis, autoimmune vasculitis, primary central nervous system vasculitis (primary angiitis of the central nervous system), subarachnoid hemorrhage (SAH), severe cerebral infarction, intracerebral hemorrhage (intracerebral
- inflammatory liver disease refers to a series of diseases accompanied by damage to liver tissue caused by direct or indirect causes of excessive or unwanted immune or inflammatory responses induced by various causes. means to encompass
- the inflammatory liver disease is viral hepatitis, toxoplasma hepatitis, alcoholic liver disease, toxic liver disease, acute and subacute liver failure.
- the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
- a lubricant e.g., a talc, a kaolin, a kaolin, a kaolin, a kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, a talct, a talct, a talct, a talct, a sorbitol, mannitol, mannitol
- the pharmaceutical composition of the present invention may be administered through various administration routes, specifically parenterally, and more specifically, oral, intravenous, arterial, subcutaneous, abdominal, intradermal, intramuscular, intraventricular, spinal Administration may be intrathecal, inhalational, nasal, intraarticular or topical.
- a suitable dosage of the pharmaceutical composition of the present invention is variously prescribed depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity of the patient. can be A preferred dosage of the pharmaceutical composition of the present invention is within the range of 0.0001-100 mg/kg for adults.
- the pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of a solution, suspension, syrup, or emulsion in oil or aqueous medium, or may be in the form of an extract, powder, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer.
- the present invention provides a method for preventing or treating inflammation or autoimmune disease, comprising administering to a subject the cerium oxide nanocomposite of the present invention or a pharmaceutical composition comprising the same as an active ingredient provides Since the cerium oxide nanocomposite used in the present invention and the inflammatory or autoimmune disease that can be prevented or treated therethrough have already been described above, the description thereof will be omitted to avoid excessive overlap.
- a method for preparing a cerium oxide nanocomposite comprising the steps of:
- R 1 and R 2 are each independently hydrogen or oxygen, represents a single bond or a double bond, l is 1 or 2, and m is an integer from 100 to 1000;
- n is an integer of 3 to 7;
- cerium oxide nanoparticles and PGA polyglutamic acid
- PASP poly (aspartic acid)]
- alginate PAA [Poly (acrylic acid)], PMAA [Poly (methacrylic) acid)], polymethyl methacrylic acid [poly(methyl methacrylic acid)], PMA [poly(maleic acid)], PBMA [poly(butadiene/maleic acid)], PVPA [Poly(vinylphosphonic acid)], PSSA [Poly( styrenesulfonic acid)], PVA (polyvinyl alcohol) and mixing at least one biocompatible dispersion stabilizer selected from the group consisting of dextran to obtain a cerium oxide nanocomposite modified with the biocompatible dispersion stabilizer.
- the term “coating” refers to forming a new layer of a certain thickness by applying a specific material on the target surface, and the target surface and the coating material may be modified through ionic or non-covalent bonding.
- non-covalent bond refers to physical bonds such as adsorption, cohesion, entanglement and entrapment, as well as interactions such as hydrogen bonds and van der Waals bonds alone or in the above physical bonds. It is a concept that includes a bond generated by acting with a bond.
- the stabilizer layer may form a sealed layer while completely surrounding the surface to be modified or may form a partially sealed layer.
- the C 1 to C 3 alcohol solvent is ethanol.
- the cerium precursor is cerium (III) acetate hydrate, cerium (III) acetylacetonate hydrate, cerium (III) carbonate hydrate, cerium (III) fluoride, cerium (III) chloride, cerium (III) chloride heptahydrate, cerium(III) bromide, cerium(III) iodide, cerium(III) nitrate hexahydrate, cerium(III) oxalate hydrate, cerium(III) sulfate and cerium(III) sulfate hydrate It is one or more precursors selected from the group consisting of. More specifically, it is cerium(III) nitrate hexahydrate.
- the heating is performed at 60 - 75 °C.
- One of the advantages of the present invention is that, unlike the prior art, which can react only for a short time at a high temperature of 95 ° C, a sufficient reaction process can be stably maintained at a temperature of around 70 ° C. It is suitable for mass production on an industrial scale. It's like a bar.
- the present invention provides a cerium oxide nanocomposite, a method for preparing the same, and a composition for preventing or treating inflammatory or autoimmune diseases comprising the same as an active ingredient.
- the present invention significantly improves the biomedical stability of nanoparticles, biocompatibility and efficiency of the production process by applying a biocompatible dispersion stabilizer consisting of an optimal combination, while maintaining the intrinsic pharmacological effect of nanoparticles, efficient nanoparticle treatment It can be usefully used as a composition.
- FIG. 1 is a diagram showing a transmission electron microscope image of a cerium oxide nanocomposite of the present invention.
- FIG. 2 is a diagram showing the results of analyzing the shape and dispersion of the cerium oxide nanocomposite according to the properties of the solvent.
- 3 is a diagram showing the change in the particle size of the cerium oxide nanocomposite according to the presence or absence of the compound.
- FIG. 4 is a diagram showing the results of analyzing the particle size change according to the content of polyvinyl pyrrolidone.
- 5 shows the results of analyzing the particle size for each reaction time of the cerium oxide nanocomposite using a dynamic light scattering device.
- FIG. 6a is a diagram showing the results of checking whether the cerium oxide nanocomposite is coated with a biocompatible dispersion stabilizer using a surface potential analysis device.
- Figure 6b shows the result of analyzing the particle size of the cerium oxide nanocomposite using a dynamic light scattering device.
- FIG. 7 is a diagram showing the evaluation results of hydrogen peroxide and hydroxyl radical removal ability of the cerium oxide nanocomposite.
- 9 is a graph showing the survival rate of 10 SD rats in the particle of the present invention, a positive control group and a negative control group, and the average value thereof is expressed as a survival rate.
- 10 is a graph showing the average survival rate of 10 C57BL/6 mice in the particles of the present invention, a positive control group and a negative control group.
- FIG. 11 is a graph showing the results of evaluating the toxic stimulus associated with reactive oxygen species after treating hepatocytes (heap-1c1c7) induced by toxic stimulus by pyrogallol with the particles of the present invention by concentration.
- a first solution was prepared by dissolving 6-aminohexanoic acid (6-AHA) (0.65585 g, Sigma-Aldrich, St. Louis, MO) in deionized water (30 mL).
- 6-AHA 6-aminohexanoic acid
- PVP polyvinylpyrrolidone
- ethyl alcohol 25 mL
- cerium (III) nitrate hexahydrate (Ce(NO 3 ) 3 .6H 2 O, 0.540 g, Alfa Aeser, Ward Hill, MA) was dissolved in ethyl alcohol (50 mL) at room temperature (about 20° C.) A fourth solution was prepared. Then, the fourth solution was added to the third solution to prepare a fifth solution. Thereafter, the temperature of the fifth solution was maintained at 70° C. for 2 hours, and then cooled to room temperature (about 20° C.). Through this process, cerium oxide nanoparticles in which 6-aminohexanoic acid and polyvinyl pyrrolidone were bonded to the surface were obtained (FIG. 1). Thereafter, the cerium oxide nanoparticles were washed three times with acetone to remove unreacted materials.
- the formation state of the cerium oxide nanocomposite was confirmed by using a 100% aqueous solvent or 70% ethyl alcohol solvent to determine the particle formation tendency according to the synthetic solvent.
- a first solution was prepared by dissolving 6-aminohexanoic acid (0.65585 g, Sigma-Aldrich, St. Louis, MO) in deionized water (30 mL) and, while stirring the first solution, polyvinyl pyrrolidone (2.0 g, Sigma-Aldrich, St. Louis, MO) was added to a second solution of deionized water (25 mL) and heated to 70° C. in air to prepare a third solution.
- cerium (III) nitrate hexahydrate (Ce(NO 3 ) 3 .6H 2 O, 0.540 g, Alfa Aeser, Ward Hill, MA) was dissolved in deionized water (50 mL) at room temperature (about 20° C.) A fourth solution was prepared. Then, the fourth solution was added to the third solution to prepare a fifth solution. Thereafter, the temperature of the fifth solution was maintained at 70° C. for 2 hours, and then cooled to room temperature (about 20° C.) to obtain cerium oxide nanoparticles in which 6-aminohexanoic acid and polyvinylpyrrolidone were bonded to the surface. Thereafter, the cerium oxide nanoparticles were washed three times with acetone to remove unreacted materials.
- Example 3 Structure formation of cerium oxide nanocomposites according to the components of the synthesis reactant
- Example 4 Changes in the formation of nanocomposites according to the content of PVP
- Example 5 Size formation trend of cerium oxide nanocomposites according to synthesis time
- Example 1 Samples were taken every 120 minutes, and particle size was analyzed using dynamic light scattering equipment. As a result, as the reaction time elapsed, the particle size gradually decreased from 30 nm to 5 nm level, and by confirming that each sample collected for each time had a very stable particle size, the method of the present invention exhibited remarkably excellent uniformity. It was confirmed that it is a process capable of producing nanoparticles (FIG. 5).
- a suspension was prepared by adding 3.5 mg of cerium oxide nanoparticles prepared through the above-described process to 0.8 mL of sodium acetate 2.5 mM buffer.
- the suspension was mixed with 0.3 ⁇ mol of polyglutamic acid (PLGA) (weight average molecular weight: 9,000) dissolved in 1.2 mL of sodium acetate buffer, or polyvinyl alcohol (PVA) (weight average molecular weight: 9,500) (weight average molecular weight: 9,500) (weight) average molecular weight: 6,000).
- PLGA polyglutamic acid
- PVA polyvinyl alcohol
- the cerium oxide nanocomposite has a surface charge value of 5 mV before coating with a biocompatible dispersion stabilizer, -40 mV after coating with PLGA, and a charge value close to -1 mV for PVA and dextran It was confirmed that each of the different biocompatible dispersion stabilizers was coated on the cerium oxide nanoparticles through the method (Fig. 6a).
- a physiological saline solution (0.9% (w/w) sodium chloride aqueous solution) dispersion environment that simulates the environment for use in actual biomedical applications, it has a size of 50 to 100 nm before coating with a biocompatible dispersion stabilizer, and each dispersion stabilizer after coating It was confirmed that the dispersion size was improved to 10-50 nm in both environments used (Fig. 6b).
- the cerium oxide nanocomposite prepared in Example 7 was administered intravenously over 5 minutes at 0.001, 0.01, 0.05, 0.1, 0.2, 0.4, 0.6 mg/kg of the cerium oxide nanocomposite prepared in Example 7 once each 1 hour after inducing the subarachnoid hemorrhage.
- the same volume of physiological saline was injected into the control SD rats while injecting with the .
- the mortality rate was significantly reduced compared to the control group.
- the mortality rate of the control group was 84.2%
- the cerium oxide nanocomposite was administered at 0.6 mg/ In the case of kg injection, it was found that the mortality rate was reduced by 18.2% (FIG. 8).
- the cerium oxide nanocomposite of the present invention was injected intravenously over 5 minutes at 0.05 mg/kg each once, and as a positive control, the conventional cerium oxide nanocomposite 0.25 mg/kg was injected into SD rats in the same manner, and the same volume of physiological saline as a control was injected into the SD rats.
- the cerium oxide nanocomposite of the present invention and the positive control showed equivalent mortality ( FIG. 9 ).
- the mortality rate of the control group was 84.2%
- the nanocomposite injection group of the present invention was 38.8%
- the positive control group was 40%.
- the cerium oxide nanocomposite of the present invention exhibited a comparable survival rate even at a dose of 1/5 of that of the positive control group, thereby showing a therapeutic effect 5 times superior to that of the positive control group.
- the novel nanocomposite of the present invention can be used as an effective composition for treating inflammatory diseases by having significantly improved therapeutic effect and stability compared to the existing cerium oxide nanocomposite.
- CLP cecal ligation and puncture
- the cerium oxide nanocomposite of the present invention was intravenously injected at 0.1 mg/kg each once, and 0.25 mg/kg of the conventional cerium oxide nanocomposite was injected as a positive control. , an equal volume of physiological saline was injected as a control. Thereafter, as a result of periodically checking the death of the C57BL/6 mice from the time of inducing sepsis to 6 days later, it was confirmed that the cerium oxide nanocomposite of the present invention significantly reduced the mortality rate compared to the positive control and the control group (FIG. 10). ). Specifically, the mortality rate of the nanocomposite injection group of the present invention was only 40%, whereas the mortality rate of the control group and the positive control group was 60% and 80%, respectively.
- the nanocomposite of the present invention is a remarkably improved technology that exhibits excellent pharmacological effect even at a low dose compared to the conventionally developed nanocomposite.
- hepatocytes heap-1c1c7
- cerium oxide nanocomposites were treated for 1 hour at each concentration to evaluate the associated toxic stimuli with active oxygen.
- FIG. 11 it was confirmed that the cerium oxide nanocomposite of the present invention significantly reduced pyrogallol-induced hepatocellular toxicity in a concentration-dependent manner.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
Claims (16)
- 다음을 포함하는 산화 세륨 나노 복합체:(a) 산화 세륨 나노입자 코어층;(b) 하기 화학식 1로 표시되는 중합체를 포함하는 내층:화학식 1(c) PGA(polyglutamic acid), PASP[poly(aspartic acid)], 알지네이트(alginate), PAA[Poly(acrylic acid)], PMAA[Poly(methacrylic acid)], 폴리메틸 메타아크릴산[poly(methyl methacrylic acid)], PMA[poly(maleic acid)], PBMA[poly(butadiene/maleic acid)], PVPA[Poly(vinylphosphonic acid)], PSSA[Poly(styrenesulfonic acid)], PVA(polyvinyl alcohol) 및 덱스트란으로 구성된 군으로부터 선택되는 하나 이상의 생체적합성 분산 안정제를 포함하는 외층.
- 제 1 항에 있어서, 상기 산화 세륨 나노입자는 산화 세륨(Ⅲ)(Ce2O3) 나노입자, 산화 세륨(Ⅳ)(CeO2) 나노입자 및 이들의 혼합물로 구성된 군으로부터 선택되는 것을 특징으로 하는 나노 복합체.
- 제 1 항에 있어서, 상기 화학식 1에서 R1은 수소이고 R2는 산소이며 l은 1인 것을 특징으로 하는 나노 복합체.
- 제 1 항에 있어서, 상기 외층에 포함된 생체적합성 분산 안정제는 PGA (polyglutamic acid)인 것을 특징으로 하는 나노 복합체.
- 제 4 항에 있어서, 상기 PGA는 PLGA(poly L-glutamic acid)인 것을 특징으로 하는 나노 복합체.
- 제 6 항에 있어서, 상기 화학식 2에서 n은 5인 것을 특징으로 하는 나노복합체.
- 제 1 항에 있어서, 상기 나노 복합체는 5 nm 내지 100 nm의 평균 입경을 가지는 것을 특징으로 하는 나노복합체.
- 제 1 항 내지 제 8 항 중 어느 한 항의 나노 복합체를 유효성분으로 포함하는 염증 또는 자가면역 질환의 예방 또는 치료용 조성물.
- 제 9 항에 있어서, 상기 염증 또는 자가면역 질환은 류마티스 관절염, 반응성 관절염, 1형 당뇨병, 전신성 홍반성 낭창, 다발성경화증, 특발성 폐섬유증, 다발성근염, 피부근염, 국한피부경화증, 전신피부경화증, 염증성 장질환, 쇼그렌증후군(Sjogren's syndrome), 레이노병(Raynaud's phenomenon), 베쳇병(Bechet's disease), 가와사키병(Kawasaki's disease), 원발성담즙성경화증(primary biliary sclerosis), 원발성경화성담관염(primary sclerosing cholangitis), 궤양성대장염(ulcerative colitis), 크론병(Crohn's disease), 건선(psoriasis), 중증근무력증(myasthenia gravis), 자가면역성 혈관염(autoimmune vasculitis), 원발성 중추신경계 혈관염(primary angiitis of the central nervous system), 지주막하출혈(subarachnoid hemorrhage; SAH), 중증 뇌경색(severe cerebral infarction), 뇌내출혈(intracerebral hemorrhage), 저산소성 허혈성 뇌병증(hypoxic ischemic encephalopathy), 외상성 뇌·척수손상(traumatic brain/spinal cord injury), 급성 호흡곤란 증후군(acute respiratory distress syndrome), 사이토카인 스톰 증후군(cytokine storm syndrome), 패혈증(sepsis) 및 염증성 간질환으로 구성된 군으로부터 선택되는 하나 이상의 질환인 것을 특징으로 하는 조성물.
- 제 10 항에 있어서, 상기 염증 또는 자가면역 질환은 지주막하출혈, 패혈증, 사이토카인 스톰 증후군(cytokine storm syndrome) 및 염증성 간질환으로 구성된 군으로부터 선택되는 것인 것을 특징으로 하는 조성물.
- 제 10 항 또는 제 11 항에 있어서, 상기 염증성 간질환은 바이러스성 간염(viral hepatitis), 톡소포자충 간염(toxoplasma hepatitis), 알콜성 간질환(alcoholic liver disease), 독성 간질환(toxic liver disease), 급성 및 아급성 간부전(Acute and subacute hepatic failure), 간농양(liver abscess), 비특이성반응성간염(Nonspecific reactive hepatitis), 간경색(liver infarction), 간정맥폐쇄질환(Hepatic veno-occlusive disease), 간 또는 담낭의 손상(Injury of liver or gallbladder), 간이식관련 간염(liver transplantation-related hepatitis)로 구성된 군으로부터 선택되는 것인 것을 특징으로 하는 조성물.
- 다음의 단계를 포함하는 산화 세륨 나노복합체의 제조 방법:(a) C1 내지 C3 알코올 용매에 세륨 전구체, 하기 화학식 1로 표시되는 중합체 및 하기 화학식 2로 표시되는 가교 화합물을 첨가하여 혼합 용액을 제조하는 단계;화학식 1화학식 2상기 화학식 2에서, n은 3 내지 7의 정수이다;(b) 상기 혼합 용액을 순차적으로 가열 및 냉각하여 산화 세륨 나노 입자를 수득하는 단계; 및(c) C1 내지 C3 알코올 용매에서 산화 세륨 나노 입자와 PGA(polyglutamic acid), PASP[poly(aspartic acid)], 알지네이트(alginate), PAA[Poly(acrylic acid)], PMAA[Poly(methacrylic acid)], 폴리메틸 메타아크릴산[poly(methyl methacrylic acid)], PMA[poly(maleic acid)], PBMA[poly(butadiene/maleic acid)], PVPA[Poly(vinylphosphonic acid)], PSSA[Poly(styrenesulfonic acid)], PVA(polyvinyl alcohol) 및 덱스트란으로 구성된 군으로부터 선택되는 하나 이상의 생체적합성 분산 안정제를 혼합하여 상기 생체적합성 분산 안정제가 개질된 산화 세륨 나노복합체를 수득하는 단계.
- 제 13 항에 있어서, 상기 C1 내지 C3 알코올 용매는 에탄올인 것을 특징으로 하는 방법.
- 제 13 항에 있어서, 상기 세륨 전구체는 세륨(Ⅲ) 아세테이트 하이드레이트, 세륨(Ⅲ) 아세틸아세토네이트 하이드레이트, 세륨(Ⅲ) 카보네이트 하이드레이트, 세륨(Ⅲ) 플루오라이드, 세륨(Ⅲ) 클로라이드, 세륨(Ⅲ) 클로라이드 헵타하이드레이트, 세륨(Ⅲ) 브로마이드, 세륨(Ⅲ) 아이오다이드, 세륨(Ⅲ) 나이트레이트 헥사하이드레이트, 세륨(Ⅲ) 옥살레이트 하이드레이트, 세륨(Ⅲ) 설페이트 및 세륨(Ⅲ) 설페이트 하이드레이트로 구성된 군으로부터 선택되는 하나 이상의 전구체인 것을 특징으로 하는 방법.
- 제 13 항에 있어서, 상기 가열은 60 - 75℃에서 이루어지는 것을 특징으로 하는 방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21774574.4A EP4129271A4 (en) | 2020-03-26 | 2021-03-25 | NEW CERIUM OXIDE NANOCOMPOSITE AND ITS USE |
AU2021244007A AU2021244007A1 (en) | 2020-03-26 | 2021-03-25 | Novel cerium oxide nanocomposite and use thereof |
CN202180022544.6A CN115335037A (zh) | 2020-03-26 | 2021-03-25 | 新型氧化铈纳米复合材料及其用途 |
CA3173622A CA3173622A1 (en) | 2020-03-26 | 2021-03-25 | Novel cerium oxide nanocomposite and use thereof |
US17/914,237 US20230114380A1 (en) | 2020-03-26 | 2021-03-25 | Novel cerium oxide nanocomposite and use thereof |
BR112022019298A BR112022019298A2 (pt) | 2020-03-26 | 2021-03-25 | Nanocompósito inovador de óxido de cério e uso do mesmo |
JP2022557793A JP2023519263A (ja) | 2020-03-26 | 2021-03-25 | 新規な酸化セリウムナノ複合体およびその用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200036974 | 2020-03-26 | ||
KR10-2020-0036974 | 2020-03-26 | ||
KR1020210038876A KR102629322B1 (ko) | 2020-03-26 | 2021-03-25 | 신규한 산화 세륨 나노 복합체 및 이의 용도 |
KR10-2021-0038876 | 2021-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021194287A1 true WO2021194287A1 (ko) | 2021-09-30 |
Family
ID=77892077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/003737 WO2021194287A1 (ko) | 2020-03-26 | 2021-03-25 | 신규한 산화 세륨 나노 복합체 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230114380A1 (ko) |
JP (1) | JP2023519263A (ko) |
AU (1) | AU2021244007A1 (ko) |
BR (1) | BR112022019298A2 (ko) |
CA (1) | CA3173622A1 (ko) |
WO (1) | WO2021194287A1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8333993B1 (en) * | 2006-12-29 | 2012-12-18 | University Of Central Florida Research Foundation, Inc. | Synthesis of polymer coated ceria nanoparticles for biomedical applications |
KR20180043989A (ko) | 2016-10-21 | 2018-05-02 | 주식회사 세닉스바이오테크 | 세리아 나노입자를 포함하는 지주막하출혈 치료용 세리아 나노복합체와 그의 제조방법, 및 약학적 조성물 |
-
2021
- 2021-03-25 JP JP2022557793A patent/JP2023519263A/ja active Pending
- 2021-03-25 CA CA3173622A patent/CA3173622A1/en active Pending
- 2021-03-25 BR BR112022019298A patent/BR112022019298A2/pt unknown
- 2021-03-25 US US17/914,237 patent/US20230114380A1/en active Pending
- 2021-03-25 WO PCT/KR2021/003737 patent/WO2021194287A1/ko active Application Filing
- 2021-03-25 AU AU2021244007A patent/AU2021244007A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8333993B1 (en) * | 2006-12-29 | 2012-12-18 | University Of Central Florida Research Foundation, Inc. | Synthesis of polymer coated ceria nanoparticles for biomedical applications |
KR20180043989A (ko) | 2016-10-21 | 2018-05-02 | 주식회사 세닉스바이오테크 | 세리아 나노입자를 포함하는 지주막하출혈 치료용 세리아 나노복합체와 그의 제조방법, 및 약학적 조성물 |
Non-Patent Citations (4)
Title |
---|
CHEN YUE, CHEN YONG, HU PENGFEI, MA SUJUAN, LI YANFEN: "The effects of PVP surfactant in the direct and indirect hydrothermal synthesis processes of ceria nanostructures", CERAMICS INTERNATIONAL, vol. 42, no. 16, 1 December 2016 (2016-12-01), NL, pages 18516 - 18520, XP055853395, ISSN: 0272-8842, DOI: 10.1016/j.ceramint.2016.08.189 * |
JEONG HAN-GIL, CHA BONG GEUN, KANG DONG-WAN, KIM DO YEON, KI SEUL KI, KIM SONG I., HAN JU HEE, YANG WOOKJIN, KIM CHI KYUNG, KIM JA: "Ceria Nanoparticles Synthesized With Aminocaproic Acid for the Treatment of Subarachnoid Hemorrhage", STROKE, vol. 49, no. 12, 1 December 2018 (2018-12-01), US, pages 3030 - 3038, XP055853391, ISSN: 0039-2499, DOI: 10.1161/STROKEAHA.118.022631 * |
PULIDO-REYES GERARDO, BRIFFA SOPHIE MARIE, HURTADO-GALLEGO JARA, YUDINA TETYANA, LEGANÉS FRANCISCO, PUNTES VICTOR, VALSAMI-JONES E: "Internalization and toxicological mechanisms of uncoated and PVP-coated cerium oxide nanoparticles in the freshwater alga Chlamydomonas reinhardtii", ENVIRONMENTAL SCIENCE: NANO, vol. 6, no. 6, 13 June 2019 (2019-06-13), GB, pages 1959 - 1972, XP055853392, ISSN: 2051-8153, DOI: 10.1039/C9EN00363K * |
REMINGTON'S PHARMACEUTICAL SCIENCES, 1995 |
Also Published As
Publication number | Publication date |
---|---|
JP2023519263A (ja) | 2023-05-10 |
US20230114380A1 (en) | 2023-04-13 |
BR112022019298A2 (pt) | 2022-11-16 |
AU2021244007A1 (en) | 2022-09-29 |
CA3173622A1 (en) | 2021-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | A dual-targeted platform based on graphene for synergistic chemo-photothermal therapy against multidrug-resistant Gram-negative bacteria and their biofilms | |
Umamaheshwari et al. | Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model | |
TWI275587B (en) | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole | |
KR102328323B1 (ko) | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 | |
WO2011105736A2 (ko) | 표면 개질된 산화탄탈륨 나노입자, 이의 제조 방법, 이를 이용한 x-선 컴퓨터 단층촬영용 조영제 및 고유전 박막 | |
WO2018074641A1 (ko) | 세리아 나노입자를 포함하는 지주막하출혈 치료용 세리아 나노복합체와 그의 제조방법, 및 약학적 조성물 | |
WO2014119836A1 (en) | Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract | |
ZA200502452B (en) | Remedy | |
WO2021194287A1 (ko) | 신규한 산화 세륨 나노 복합체 및 이의 용도 | |
KR102629322B1 (ko) | 신규한 산화 세륨 나노 복합체 및 이의 용도 | |
KR101415221B1 (ko) | 무기 나노입자를 유효성분으로 함유하는 혈관 신생 관련 질환의 예방 및 치료용 조성물 | |
WO2017143967A1 (zh) | 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途 | |
WO2018044035A1 (ko) | 수중유형 화장료 조성물 | |
WO2018124363A1 (ko) | 생체의학적 치료용 세리아 나노복합체 및 이를 포함하는 약학적 조성물 | |
WO2018236090A2 (ko) | 키토산-플루로닉 복합체 및 이를 포함하는 나노운반체 | |
TW201615694A (zh) | 主鏈型聚胺類 | |
US20220288162A1 (en) | Process and composition matter of nanoparticle formulation for systemic treatment of sepsis | |
US20230099752A1 (en) | Novel cerium oxide nanocomplex and a composition for preventing or treating peritonitis comprising the same | |
AU2020201037B1 (en) | Mesoporous silica nanoparticle composite for biomedical treatment, method of producing the same, and pharmaceutical composition including the same | |
WO2021261941A1 (ko) | 기능화된 전이금속 디칼코게나이드를 포함하는 패혈증 예방 또는 치료용 약학적 조성물 | |
JP2019001786A (ja) | 感染症治療薬 | |
US20230089986A1 (en) | Novel cerium oxide nanocomplex and a composition for preventing or treating cerebral infarction comprising the same | |
WO2018153349A1 (zh) | 一种MMT-Gd-DTPA复合物及其合成方法和在消化道磁共振诊断中的应用 | |
Huang et al. | Biomimetic Metal–Organic Framework Gated Nanoplatform for Sonodynamic Therapy against Extensively Drug Resistant Bacterial Lung Infection | |
WO2011115342A1 (ko) | 소장의 조영을 위한 경구용 조영제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21774574 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3173622 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022557793 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021244007 Country of ref document: AU Date of ref document: 20210325 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022019298 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202217058224 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021774574 Country of ref document: EP Effective date: 20221026 |
|
ENP | Entry into the national phase |
Ref document number: 112022019298 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220926 |